Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.65 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036744 | 1.00 | NPFFR1 (0.65) | NPFFR1NPFFR2HPGDGFERALDH1A1 | |
| SCHEMBL28341134 | 0.81 | HPGD (0.68) | HPGDGFERALDH1A1TSHRKMT2A | |
| SCHEMBL874443 | 0.79 | GFER (0.58) | HPGDGFERALDH1A1TSHRKMT2A | |
| SCHEMBL29509920 | 0.78 | GFER (0.57) | HPGDGFERALDH1A1TSHRKMT2A | |
| SCHEMBL27961040 | 0.78 | HPGD (0.64) | HPGDGFERALDH1A1TSHRKMT2A | |
| SCHEMBL273196 | 0.78 | HPGD (0.64) | HPGDGFERALDH1A1TSHRKMT2A | |
| Water SCHEMBL9518556 | 0.76 | HPGD (0.61) | HPGDGFERALDH1A1TSHRKMT2A | |
| SCHEMBL28351690 | 0.74 | HPGD (0.52) | HPGDGFERALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL17988323 | 0.74 | HPGD (0.52) | HPGDGFERALDH1A1TSHRKMT2A | |
| SCHEMBL17548937 | 0.73 | ESR1 (0.59) | HPGDGFERALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | VAN LOMMEN GUY ROSALIA EUGEEN | 2009-07-30 | — | — | US | disclosed |
| US-7511068-B2 | Mercaptoimidazoles as CCR2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | LOMMEN GUY R E | 2007-07-19 | — | — | US | disclosed |
| EP-1778646-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-02 | — | — | EP | disclosed |
| US-20060058289-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| WO-2006015986-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| EP-1592670-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069810-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069809-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058289-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | CCR2, CCR5, CXCR3 | NPFFR1 289/4885NPFFR2 278/4885HPGD 800/4885 |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | CCR2, CCR1, CCR5 | NPFFR1 412/4885NPFFR2 882/4885HPGD 1963/4885 |
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR1, CXCR3 | NPFFR1 507/4885NPFFR2 1181/4885HPGD 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.